Browsing Tag
Muthalagu Ramanathan
1 post
Exicure completes Phase 2 trial of GPC-100 for stem cell mobilization in multiple myeloma patients
Exicure (NASDAQ: XCUR) completes final patient visit in Phase 2 GPC-100 trial for stem cell mobilization in multiple myeloma; topline results expected Q4 2025.